Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Neurotech International ( (AU:NTI) ) is now available.
Neurotech International has announced the publication of its Phase I/II clinical trial results for Rett syndrome in the Journal of Paediatrics and Child Health. The study highlights the potential of NTI164, a full-spectrum medicinal cannabis plant extract, in improving symptoms of Rett syndrome, with observed clinical improvements in neurological, behavioural, and functional measures. This publication underscores the scientific and clinical merit of NTI164, reinforcing its potential for future regulatory advancement and offering hope for novel therapeutic options in paediatric neurological conditions.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company that focuses on developing treatments for paediatric neurological disorders. The company is known for its broad-spectrum oral cannabinoid drug therapy, NTI164, which has shown promising results in clinical trials for conditions such as Autism Spectrum Disorder, Rett Syndrome, and PANDAS/PANS.
Average Trading Volume: 638,185
Technical Sentiment Signal: Sell
Current Market Cap: A$19.94M
See more data about NTI stock on TipRanks’ Stock Analysis page.